AstraZeneca PLC (OTCMKTS:AZNCF) Sees Large Decline in Short Interest

AstraZeneca PLC (OTCMKTS:AZNCFGet Free Report) was the target of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 82,300 shares, a decrease of 9.2% from the April 30th total of 90,600 shares. Based on an average daily volume of 6,000 shares, the short-interest ratio is currently 13.7 days.

AstraZeneca Stock Up 5.2 %

Shares of AstraZeneca stock opened at $153.78 on Friday. AstraZeneca has a 52 week low of $118.16 and a 52 week high of $159.84. The business’s fifty day simple moving average is $145.03 and its 200-day simple moving average is $135.46.

Hedge Funds Weigh In On AstraZeneca

An institutional investor recently bought a new position in AstraZeneca stock. Kennedy Capital Management LLC acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCFFree Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 37,554 shares of the company’s stock, valued at approximately $5,068,000. Institutional investors own 40.87% of the company’s stock.

About AstraZeneca

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

See Also

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.